期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 117, 期 6, 页码 1466-1476出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI32446
关键词
-
资金
- NCI NIH HHS [R01 CA105216, 5R01CA105216, P50 CA083638, 5P50CA083638, R01 CA105216-03, 1R01CA104679] Funding Source: Medline
The transfusion of lymphocytes, referred to as adoptive T cell therapy, is being tested for the treatment of cancer and chronic infections. Adoptive T cell therapy has the potential to enhance antitumor immunity, augment vaccine efficacy, and limit graft-versus-host disease. This form of personalized medicine is now in various early- and late-stage clinical trials. These trials are currently testing strategies to infuse tumor-infiltrating lymphocytes, CTLs, Th cells, and Tregs. Improved molecular biolo techniques have also increased enthusiasm and feasibility for testing genetically engineered T cells. The current status of the field and prospects for clinical translation are reviewed herein.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据